

DCF Psychotropic Medication Advisory Committee
Monthly Meeting Notes

April 1, 2011 1:30PM

Riverview Hospital for Children and Youth
Middletown, CT.

PRESENT: See enclosed attendance record.

1. Call to order: the meeting was called to order at 1:31 pm by Dr. Siegel. It was noted that there was not a quorum present (51% of members AND present members must include at least 1 psychiatrist, 1 pediatrician, 1 pharmacist, and 1 nurse). A recommendation was made to change the policy and eliminate the requirement of a pediatrician being present (no vote taken due to lack of a quorum).
2. Next Meeting: The meetings for the remainder of 2010 will take place on May 6th, June 3rd, September 9th, October 7th, November 4th and December 2nd. The committee will not meet in July or August. Meetings will be from 1:00pm – 2:30pm; RHCY AB conference room.
3. The minutes of the March 2011 PMAC meeting were reviewed and approved with one correction. The time of the meeting changed to 1pm-230pm. The minutes will be posted on the website.
4. DSS: Cheryl Wamuo reported: An eligibility response quick reference guide was distributed, reviewed and discussed (attached). It was noted there are many changes to the Medicaid program that will be rolled out soon. Items discussed include:
 - Husky vs Managed Care vs straight Title 19.
 - Changes: many programs will change as of Jan 2012. Husky will be eliminated and all patients will be on straight Title 19 (except behavioral health which will stay with Value Options as an Administrative Service Organization (ASO)). The ASO will use case managers.
 - RFPs went out for ASO's for medical patients.
 - There may be some co-pays however a request has been submitted to exempt DCF from the co-pay requirement.
 - Various waivers were discussed.
 - Charter Oak discussed. There will be not changes to this plan.
 - The following will be placed on the agenda for next month's DSS report.
 1. Planned changes for Jan 2012.
 2. System of care referral.
 3. Pharmacy Services Drug Utilization Letters (using PMAC guidelines).
5. Recommended Changes to the Approved Drug List: Deletions.
 - Loxapine, Thiothixene, Chlordiazepoxide, Amantadine: Defer to next meeting.

6. Recommended Changes to the Approved Drug List: Additions. Drug information monographs were distributed for each of the medications noted below (No vote taken due to lack of quorum).
- Paliperidone, Asenapine, Lurasidone: There is not evidenced based information on these medications for use in children.
 - Venlafaxine: there is not additional data since the last official review on the use or efficacy for the use of this drug in children for depression. There was one study noted that compared venlafaxine to methylphenidate for treating ADHD. Efficacy was comparable and methylphenidate had a higher rate of side effects. Efficacy, discontinuation syndrome and other issues were discussed. Data on an SSRI study were reviewed and discussed (study enclosed).
 - There was a long discussion on the topic of pharmacoeconomics. The pros and cons of including this as a criteria for Approved Drug List evaluation was discussed.
 - Drug Status on the Approved Drug List will be placed on next months agenda.
 1. On list post evaluation (approved)
 2. Not on list post evaluation (not approved)
 3. On list post evaluation (restricted)
 - PMAC Bylaws: Dr. Siegel recommended that the PMAC bylaws be reviewed in the next meeting.
7. Adjournment: The meeting was adjourned at 3pm.

Respectfully Submitted:

David S. Aresco